Chemistry Reference
In-Depth Information
[81] Conde S, Pérez DI, Martínez A, Perez C, Moreno FJ. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of
glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem., 2003; 46: 4631-4633.
[82] Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, Kalisz HM, Flocco M. Structural characterization
of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol., 2003; 333: 393-407.
[83] Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, Radesäter AC, Jerning E, Markgren PO, Borgegård T, Nylöf M,
Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J. Structural insights and biological effects of glycogen
synthase kinase 3-specific inhibitor AR-A014418 J. Biol. Chem. 2003; 278:45937-45945
[84] Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica C. A, Brivanlou A,
Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P. GSK-3-selective inhibitors derived from
Tyrian purple indirubins. Chem. Biol., 2003; 10: 1255-1266.
[85] Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM,
Pearl L, Leost M, Greengard P, Meijer L. Structural basis for the synthesis of indirubins as potent and selective inhibitors
of glycogen synthase kinase-3 and cyclin-dependent kinases, J. Med. Chem. 2004; 47: 935-946.
[86] Witherington J, Bordas V, Haigh D, Hickey DM, Ife RJ, Rawlings AD, Slingsby BP, Smith DG, Ward R W. 5-aryl-
pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2003; 13,
1581-1584.
[87] Fischer PM. CDK versus GSK-3 inhibition: a purple haze no longer? Chem. Biol. 2003; 10, 1144-1146.
[88] Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas P C, Wu YZ,
Biernat J, Mandelkow EM, Kim SH, Pettit GR. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by
hymenialdisine, a marine sponge constituent. Chem. Biol. 2000; 7: 51-63.
[89] Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM,
Eisenbrand G, Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved
in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
J. Biol. Chem. 2001; 276: 251-260.
[90] Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003;
371: 199-204.
[91] Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW,
Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L. Paullones are potent inhibitors of glycogen synthase
kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem., 2000; 267: 5983-5994.
[92] Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase
kinase-3 beta. Bioorg. Med. Chem. Lett. 2004; 14: 413-416.
[93] Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond J M, Meijer L.
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme
selectivity, and cellular effects. J. Med. Chem. 2003; 46, 222-236.
[94] Naerum L, Nørskov-Lauritsen L, Olesen PH. Scaffold hopping and optimization towards libraries of glycogen synthase
kinase-3 inhibitors. Bioorg.Med. Chem. Lett. 2002; 12, 1525-1528.
[95] Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, ReederJW, Samuels I, Slabiak T, Wagman
AS, Hammond ME, Harrison SD. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose
transport and utilization
in vitro
and in vivo. Diabetes 2003; 52: 588-595.
[96] Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2
diabetes. Curr. Pharmacol. Des. 2004; 10: 1105-1137.
[97] Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, Meijer L, Monge A. Pyrazolo[3,4-b]quinoxalines. A
new class of cyclin-dependent kinases inhibitors. Bioorg. Med. Chem. 2002; 10: 2177-2184.
[98] Lane ME, Yu B, Rice A, Lipson KE, Liang C, Sun L, Tang C, McMahon G, Pestell RG, Wadler SA. Novel cdk2-selective
inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001; 61: 6170-6177.
[99] Zhang HC, White KB, Ye H, McComsey DF, Derian CK, Addo MF, Andrade-Gordon P, Eckardt AJ, Conway BR,
Westover L, Xu JZ, Look R, Demarest KT, Emanuel S, Maryanoff BE. Macrocyclic bisindolylmaleimides as inhibitors of
protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2003; 13, 3049-3053.
[100] Kuo GH, Prouty C, DeAngelis A, Shen L, O'Neill DJ, Shah C, Connolly PJ, Murray WV, Conway BR, Cheung P,
Westover L, Xu JZ, Look RA, Demarest KT, Emanuel S, Middleton SA, Jolliffe L, Beavers MP, Chen X. Synthesis and
discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective
glycogen synthase kinase-3beta inhibitors. J. Med. Chem. 2003; 46, 4021-4031.
[101] Shen L, Prouty C, Conway BR, Westover L, Xu JZ, Look RA. Chen X, Beavers MP, Roberts J, Murray WV, Demarest
KT, Kuo GH. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly
selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors. Bioorg.Med. Chem. 2004; 12: 1239-1255.
